JP2022141916A5 - - Google Patents

Download PDF

Info

Publication number
JP2022141916A5
JP2022141916A5 JP2022119166A JP2022119166A JP2022141916A5 JP 2022141916 A5 JP2022141916 A5 JP 2022141916A5 JP 2022119166 A JP2022119166 A JP 2022119166A JP 2022119166 A JP2022119166 A JP 2022119166A JP 2022141916 A5 JP2022141916 A5 JP 2022141916A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
lymphoma
cell lymphoma
inhibitor
cdk inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022119166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022141916A (ja
JP7416872B2 (ja
Filing date
Publication date
Priority claimed from JP2018550790A external-priority patent/JP7114478B2/ja
Application filed filed Critical
Publication of JP2022141916A publication Critical patent/JP2022141916A/ja
Publication of JP2022141916A5 publication Critical patent/JP2022141916A5/ja
Priority to JP2023223257A priority Critical patent/JP2024038227A/ja
Application granted granted Critical
Publication of JP7416872B2 publication Critical patent/JP7416872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022119166A 2016-03-28 2022-07-27 癌の治療のための配合剤 Active JP7416872B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023223257A JP2024038227A (ja) 2016-03-28 2023-12-28 癌の治療のための配合剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662314356P 2016-03-28 2016-03-28
US62/314,356 2016-03-28
JP2018550790A JP7114478B2 (ja) 2016-03-28 2017-03-28 癌の治療のための配合剤
PCT/US2017/024618 WO2017172826A1 (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018550790A Division JP7114478B2 (ja) 2016-03-28 2017-03-28 癌の治療のための配合剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023223257A Division JP2024038227A (ja) 2016-03-28 2023-12-28 癌の治療のための配合剤

Publications (3)

Publication Number Publication Date
JP2022141916A JP2022141916A (ja) 2022-09-29
JP2022141916A5 true JP2022141916A5 (cg-RX-API-DMAC10.html) 2022-10-07
JP7416872B2 JP7416872B2 (ja) 2024-01-17

Family

ID=59966407

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018550790A Active JP7114478B2 (ja) 2016-03-28 2017-03-28 癌の治療のための配合剤
JP2022119166A Active JP7416872B2 (ja) 2016-03-28 2022-07-27 癌の治療のための配合剤
JP2023223257A Pending JP2024038227A (ja) 2016-03-28 2023-12-28 癌の治療のための配合剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018550790A Active JP7114478B2 (ja) 2016-03-28 2017-03-28 癌の治療のための配合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023223257A Pending JP2024038227A (ja) 2016-03-28 2023-12-28 癌の治療のための配合剤

Country Status (13)

Country Link
US (6) US11135198B2 (cg-RX-API-DMAC10.html)
EP (1) EP3436002B1 (cg-RX-API-DMAC10.html)
JP (3) JP7114478B2 (cg-RX-API-DMAC10.html)
KR (5) KR102599512B1 (cg-RX-API-DMAC10.html)
CN (1) CN109689047B (cg-RX-API-DMAC10.html)
AU (4) AU2017241914B2 (cg-RX-API-DMAC10.html)
CA (2) CA3103604C (cg-RX-API-DMAC10.html)
IL (3) IL295472B2 (cg-RX-API-DMAC10.html)
MX (3) MX2018011666A (cg-RX-API-DMAC10.html)
NZ (1) NZ747404A (cg-RX-API-DMAC10.html)
RU (1) RU2726367C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017172826A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA201806819B (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
IL295472B2 (en) * 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
CN111727059A (zh) * 2017-10-31 2020-09-29 卫材研究发展管理有限公司 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法
CN108261414B (zh) * 2018-01-11 2019-09-06 广西师范大学 一种治疗肺癌的药物组合物
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
WO2020036995A1 (en) * 2018-08-14 2020-02-20 Mei Pharma, Inc. Combination therapy
WO2020092615A1 (en) * 2018-11-01 2020-05-07 Oregon Health & Science University Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia
IL286993B2 (en) 2019-04-11 2026-04-01 Mei Pharma Inc Polymorphs of vorocicliv and methods for their preparation and use
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
US12679842B2 (en) 2019-10-08 2026-07-14 Dana-Farber Cancer Institute, Inc. HCK as a therapeutic target in MYD88 mutated diseases
AU2021268195A1 (en) * 2020-05-07 2022-09-29 Recurium Ip Holdings, Llc Combinations
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
AU2021381423A1 (en) * 2020-11-19 2023-06-22 Mei Pharma, Inc. Treatment of kras mutant cancers
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
CA3214517A1 (en) * 2021-04-10 2022-10-13 Daniel Gold Voruciclib dosing regimens and methods of treatment including the same
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Bcl 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
EP1888543B1 (en) 2005-05-24 2012-08-01 Abbott Laboratories Apoptosis promoters
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
KR101209397B1 (ko) 2006-06-21 2012-12-06 피라말 라이프 사이언시스 리미티드 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법
CA2687204C (en) * 2007-05-15 2015-11-24 Piramal Life Sciences Limited A synergistic pharmaceutical combination for the treatment of cancer
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
EP2376085B1 (en) 2008-12-19 2014-02-26 Genentech, Inc. Compounds and methods of use
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
JP6501264B2 (ja) * 2012-07-24 2019-04-17 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US9241941B2 (en) * 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
EP2945940B1 (en) 2013-01-16 2020-07-15 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
SG11201507106PA (en) * 2013-03-14 2015-10-29 Onyx Therapeutics Inc Dipeptide and tripeptide epoxy ketone protease inhibitors
CA3280124A1 (en) * 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
US10314842B2 (en) * 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
US9925192B2 (en) 2014-02-28 2018-03-27 Merck Sharp & Dohme Corp. Method for treating cancer
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
US9637488B2 (en) * 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
IL295472B2 (en) 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2019514854A5 (cg-RX-API-DMAC10.html)
RU2018137687A (ru) Фармацевтические комбинации для лечения злокачественной опухоли
DE60118571T2 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
TW202327569A (zh) 包含tead抑制劑的藥物組合及其用於癌症治療之用途
EP3490553B1 (en) Combination comprising an indolinone compound and its use in the treatment of lymphoma
JP2020505433A5 (cg-RX-API-DMAC10.html)
CN1315479C (zh) 橄榄苦苷在制备抑制血管生成药物中的用途
JP2015535291A (ja) 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療
AU2002311985A1 (en) Methods for inhibiting angiogenesis
WO2024216151A1 (en) Combination therapy for treating hematological cancers
ES2698363T3 (es) Composiciones de oxprenolol para tratar el cáncer
JP2022507025A5 (cg-RX-API-DMAC10.html)
WO2023114871A1 (en) Use of combination therapy for treating cancer
CN116635074A (zh) 用于治疗pik3ca突变癌症的组合疗法
CN116270644A (zh) Cdk9抑制剂与bcl-2抑制剂联用的药物组合及其用途
US20200352932A1 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN109876000A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
JP2021522246A5 (cg-RX-API-DMAC10.html)
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
US12377089B2 (en) Quinoline derivative used for soft tissue sarcoma combination therapy
WO2024249837A1 (en) Methods of treating cancer in bcl2 inhibitor naive subjects
AU2024281302A1 (en) Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure
WO1992011247A1 (fr) Composition anticancereuse et compose
CN101568341A (zh) 用于治疗耳鸣和耳聋的包含nk-1受体拮抗剂和ssri的组合物
TW202340142A (zh) Gcl抑制劑